retatrutide
Manufactured by Eli Lilly
First of its kind: Retatrutide is not yet FDA-approved. It cannot legally be prescribed or dispensed by any pharmacy in the United States. Vials sold online with research-use-only labels are unregulated. This entry tracks the science and timeline; see /retatrutide for the full guide.
Compounded — Consider FDA-Approved Brands
Compounded retatrutide is legally restricted as of 2025 after the FDA declared the shortage resolved. If you're currently using a compounded version, consider switching to an FDA-approved brand.
Retatrutide
Eli Lilly's next-generation triple-agonist (GLP-1 + GIP + glucagon) weight loss injection. In late Phase 3 trials. Phase 2 results showed 24.2% body weight reduction at 48 weeks. Expected FDA decision late 2026 to early 2027.
See Retatrutide savings and coverage →Overview
FDA Status
Not FDA Approved
Route
subcutaneous injection
Dosing
Typical Dose Range
1mg - 12mg weekly (Phase 3 dose range)
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Cost Breakdown
Branded (Retail)
N/A
Savings Program
N/A
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
Common Side Effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- transient heart rate increase
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Related Articles
Retatrutide Delivers Record 2% A1C Drop and 16.8% Weight Loss in Diabetes Trial
Eli Lilly's triple-agonist retatrutide achieved up to 2% A1C reduction and 36.6 pounds of weight loss in its first Phase 3 diabetes trial, marking a potential new standard for type 2 diabetes treatment.
The DoseLilly's Retatrutide Delivers Record 28.7% Weight Loss in First Phase 3 Trial
Eli Lilly's triple-agonist retatrutide achieved 28.7% average weight loss (71.2 pounds) in its first successful Phase 3 trial, setting a new efficacy record for obesity medications.
The DoseEli Lilly's Triple Agonist Retatrutide Achieves 2% A1C Drop in Phase 3
Lilly's experimental retatrutide delivered up to 2% A1C reduction and 16.8% weight loss in its first Phase 3 diabetes trial, positioning it as a potential challenger to current GLP-1 therapies.
MedicationsWhat Is Retatrutide? The Next-Gen Weight Loss Drug Explained
Everything known about retatrutide, the triple-agonist weight loss drug in late-stage clinical trials, including Phase 2 data showing up to 24% weight loss, how it compares to semaglutide and tirzepatide, and when it might be available.